HIV-GenomePro Platform – Witec AG

Unleash the Power of Deep Sequencing: Our HIV Drug Resistance Platform

Traditional methods for detecting HIV drug resistance (HIVDR) rely on Sanger sequencing. However, this technology suffers from limitations:

• Low Throughput: It can only analyze a small number of samples at a time.
• Limited Sensitivity: It struggles to detect rare drug-resistant variants.

MGI's cutting-edge platform addresses these challenges by leveraging massively parallel sequencing (MPS) technology. This advanced approach allows us to:

• Analyze large sample volumes efficiently.
• Detect even the rarest drug-resistant variants with exceptional sensitivity.

Here's how it works:

1. Targeted Sequencing: We analyze specific HIV gene regions using MPS.
2. Comprehensive Analysis: Sequenced data is compared to known wild-type and drug-resistant strains to identify potential mutations related to drug resistance.
3. Expert Interpretation: A sophisticated drug resistance explanation system determines the level and type of drug resistance present.

Unmatched Functionality:

• Automated Analysis: Streamline your workflow with features like:
  • Genotype/subtype annotation
  • Data quality control
  • Coverage statistics
  • HIV concentration calculation
• Advanced Insights: Gain deeper understanding with:
  • PR-RT-IN gene assembly
  • Virus evolution tracing analysis
  • SNP and InDel detection
• Drug Resistance Expertise: Utilize drug resistance annotations based on the Stanford University HIVDB database.
• Network Analysis Integration: Integrate with HIV-TRACE for advanced network analysis of viral mutations.